Andra AP fonden lifted its holdings in shares of Baxter International Inc (NYSE:BAX) by 34.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 119,500 shares of the medical instruments supplier’s stock after buying an additional 30,900 shares during the period. Andra AP fonden’s holdings in Baxter International were worth $9,212,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Natixis raised its holdings in shares of Baxter International by 62.5% in the 2nd quarter. Natixis now owns 716,411 shares of the medical instruments supplier’s stock valued at $52,900,000 after purchasing an additional 275,452 shares during the period. AMP Capital Investors Ltd raised its holdings in shares of Baxter International by 1.5% in the 2nd quarter. AMP Capital Investors Ltd now owns 267,439 shares of the medical instruments supplier’s stock valued at $19,749,000 after purchasing an additional 3,839 shares during the period. First Hawaiian Bank bought a new stake in shares of Baxter International in the 3rd quarter valued at about $1,639,000. Putnam Investments LLC raised its holdings in shares of Baxter International by 33.9% in the 2nd quarter. Putnam Investments LLC now owns 1,330,139 shares of the medical instruments supplier’s stock valued at $98,217,000 after purchasing an additional 336,950 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Baxter International by 6.1% in the 2nd quarter. Swiss National Bank now owns 2,191,439 shares of the medical instruments supplier’s stock valued at $161,816,000 after purchasing an additional 125,700 shares during the period. Institutional investors own 82.28% of the company’s stock.
Shares of NYSE:BAX traded up $0.37 on Thursday, reaching $63.87. 3,232,311 shares of the company’s stock were exchanged, compared to its average volume of 3,155,483. Baxter International Inc has a twelve month low of $61.05 and a twelve month high of $78.38. The firm has a market cap of $33.75 billion, a PE ratio of 25.75, a PEG ratio of 1.71 and a beta of 1.02. The company has a quick ratio of 2.00, a current ratio of 2.60 and a debt-to-equity ratio of 0.38.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $87.00 target price on the stock in a report on Tuesday, September 25th. Argus reaffirmed a “hold” rating on shares of Baxter International in a report on Tuesday, September 4th. JPMorgan Chase & Co. upped their target price on shares of Baxter International from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Friday, July 27th. Royal Bank of Canada reissued a “hold” rating and issued a $76.00 price target on shares of Baxter International in a report on Friday, July 27th. Finally, Piper Jaffray Companies increased their price target on shares of Baxter International from $77.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, July 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the stock. Baxter International presently has an average rating of “Buy” and a consensus price target of $75.25.
In related news, SVP Giuseppe Accogli sold 17,647 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.27, for a total transaction of $1,363,583.69. Following the sale, the senior vice president now owns 59,452 shares in the company, valued at approximately $4,593,856.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.
Baxter International Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: Technical Analysis
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.